Symphogen A/S

LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge

• The LAG-3 inhibitors market is poised for substantial growth, projected to exceed USD 3 billion by 2029, driven by increasing adoption in cancer therapy. • Opdualag, the first approved LAG-3 therapy, has demonstrated significant commercial success, generating substantial revenue and paving the way for further drug development. • Clinical trials are actively evaluating LAG-3 inhibitors in combination with other therapies, showing potential across various cancers, autoimmune disorders, and inflammatory diseases. • Several LAG-3 inhibitor candidates are in late-stage clinical trials, indicating a robust pipeline and growing interest from major pharmaceutical companies.